(Q34014393)

30 July 2017

1 reference

title

New approaches in the treatment of type 2 diabetes (English)

1 reference

30 July 2017

0 references

B B Zhang

1

1 reference

30 July 2017

D E Moller

series ordinal

2

1 reference

30 July 2017

publication date

1 August 2000

1 reference

Current Opinion in Chemical Biology

30 July 2017

published in

1 reference

30 July 2017

volume

4

1 reference

30 July 2017

issue

4

1 reference

30 July 2017

page(s)

461-467

1 reference

Pharmacologic therapy for type 2 diabetes mellitus

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900103-4

7 January 2021

PPAR-gamma: adipogenic regulator and thiazolidinedione receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900103-4

7 January 2021

PPARgamma: an essential regulator of adipogenesis and modulator of fat cell function

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900103-4

7 January 2021

PPAR gamma is required for placental, cardiac, and adipose tissue development

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900103-4

7 January 2021

PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900103-4

7 January 2021

PPARγ Is Required for the Differentiation of Adipose Tissue In Vivo and In Vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900103-4

7 January 2021

Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900103-4

7 January 2021

A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900103-4

7 January 2021

Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900103-4

7 January 2021

A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900103-4

7 January 2021

A synthetic antagonist for the peroxisome proliferator-activated receptor gamma inhibits adipocyte differentiation

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900103-4

7 January 2021

A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900103-4

7 January 2021

Recent update on the PPARα-null mouse

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900103-4

7 January 2021

Peroxisomal and mitochondrial fatty acid beta-oxidation in mice nullizygous for both peroxisome proliferator-activated receptor alpha and peroxisomal fatty acyl-CoA oxidase. Genotype correlation with fatty liver phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900103-4

7 January 2021

Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900103-4

7 January 2021

A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipid-lowering activity

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900103-4

7 January 2021

A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900103-4

7 January 2021

Regulation of Lipoprotein Metabolism by Thiazolidinediones Occurs through a Distinct but Complementary Mechanism Relative to Fibrates

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900103-4

7 January 2021

The roles of insulin and glucagon in the regulation of hepatic glycogen synthesis and turnover in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900103-4

7 January 2021

Immunoneutralization of endogenous glucagon with monoclonal glucagon antibody normalizes hyperglycaemia in moderately streptozotocin-diabetic rats

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900103-4

7 January 2021

Synthetic peptide antagonists of glucagon

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900103-4

7 January 2021

Pure glucagon antagonists: biological activities and cAMP accumulation using phosphodiesterase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900103-4

7 January 2021

Molecular characterization of a common binding site for small molecules within the transmembrane domain of G-protein coupled receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900103-4

7 January 2021

Discovery and structure-activity relationship of the first non-peptide competitive human glucagon receptor antagonists.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900103-4

7 January 2021

Characterization of a novel, non-peptidyl antagonist of the human glucagon receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900103-4

7 January 2021

Potent, orally absorbed glucagon receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900103-4

7 January 2021

Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900103-4

7 January 2021

Plasma glucose levels are reduced in rats and mice treated with an inhibitor of glucose-6-phosphate translocase

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900103-4

7 January 2021

Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900103-4

7 January 2021

A synthetic glucagon-like peptide-1 analog with improved plasma stability

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900103-4

7 January 2021

Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900103-4

7 January 2021

Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900103-4

7 January 2021

Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900103-4

7 January 2021

Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900103-4

7 January 2021

Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900103-4

7 January 2021

Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900103-4

7 January 2021

Deconstructing type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900103-4

7 January 2021

Tissue-specific insulin resistance in mice with mutations in the insulin receptor, IRS-1, and IRS-2.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900103-4

7 January 2021

Discovery of a Small Molecule Insulin Mimetic with Antidiabetic Activity in Mice

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900103-4

7 January 2021

In vivo and in vitro studies of vanadate in human and rodent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900103-4

7 January 2021

Mechanism of inhibition of protein-tyrosine phosphatases by vanadate and pervanadate

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900103-4

7 January 2021

Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900103-4

7 January 2021

10.1016/S1367-5931(00)00103-4

Identifiers

DOI

1 reference

30 July 2017

1 reference